261 Ces Urol 2023; 27(3): 251-261 PŮVODNÍ PRÁCE 10. Petrelli F, Coinu A, Cabiddu M, et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta‑analysis. Eur Urol. 2014 Feb; 65(2): 350–7. doi: 1.1016/j.eururo.2013. 06. 049. 11. Hermans TJ, Fransen van de Putte EE, et al. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node‑positive bladder cancer‑Results of a nationwide population‑based study. Eur J Cancer. 2016; 69: 1-8. doi: 10.1016/j.ejca.2016. 09. 015. 12. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a co‑ operative group report. J Clin Oncol 2004; 22(14): 2781–2789. 13. Gschwend JE, Heck MM, Lehmann J, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol. 2019 Apr; 75(4): 604–611. doi: 10.1016/j.eururo.2018. 09. 047. 14. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high‑dose‑intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony‑stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organisation for Research and Treatment of Cancer Protocol No. 30924 J Clin Oncol. 2021; 19: 2638– 2646. 15. Pfister C, Gravis G, Fléchon A, et al. VESPER Trial Investigators. Dose‑Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle‑Invasive Bladder Cancer: Results of the GETUG‑AFU V05 VESPER Trial. J Clin Oncol. 2022 Jun 20; 40(18): 2013–2022. doi: 10.1200/JCO.21.02051. 16. Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystecto‑ my in Patients With Muscle‑Invasive Urothelial Bladder Carcinoma (PURE-01): An Open‑Label, Single‑Arm, Phase II Study. J Clin Oncol. 2018; 36: 3353. 17. Powles T, Kockx M, Rodriguez‑Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019; 25: 1706. 18. Powles TB, PerezValderamma B, Gupta S, et al. EV-302/KEYNOTE‑A39: Open‑label, randomized phase 3 study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). ESMO Congress. 2023; Abstract LBA6. 19. Crozier J, Papa N, Perera M, et al. Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta‑analysis. World J Urol. 2019 Apr; 37(4): 667–690. doi: 10.1007/s00345-018-2439-8.
RkJQdWJsaXNoZXIy NDA4Mjc=